NCT03530878

Mild Hip Dysplasia

Withdrawn NA Last updated 26 February 2019

What this trial tests

NA trial testing Hip Arthroscopy in Hip Dysplasia. Withdrawn.

Timeline

1 June 2018

Primary endpoint
11 January 2019

11 January 2019

Quick facts

Lead sponsor	Mayo Clinic
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	1 June 2018
Primary completion	11 January 2019
Estimated completion	11 January 2019

Drugs / interventions tested

• Hip Arthroscopy

Conditions studied

• Hip Dysplasia — all drugs for Hip Dysplasia →

Sponsor

Mayo Clinic

Who can join

Adults 18 to 45, any sex, with Hip Dysplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hip dysplasia is a complex problem that exists on a spectrum from mild to severe disease. Periacetabular osteotomy (PAO) remains the gold standard for most patients with dysplasia; however, the procedure is quite invasive making the decision to proceed in cases of mild disease difficult. Hip arthroscopy (HA) is an alternative minimally invasive technique that can be used to address mild dysplasia. Nevertheless, HA has less capability for correction and in rare instances can exacerbate instability in the dysplastic hip. There is a paucity of data examining outcomes between these two treatment strategies for this challenging problem.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.